Deep Dive Into Fortrea Holdings Stock: Analyst Perspectives (7 Ratings)
7 analysts have expressed a variety of opinions on Fortrea Holdings (NASDAQ:FTRE) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 2 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $18.14, with a high estimate of $25.00 and a low estimate of $13.00. This upward trend is apparent, with the current average reflecting a 49.42% increase from the previous average price target of $12.14.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Fortrea Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Eric Coldwell | Baird | Lowers | Outperform | $16.00 | $19.00 |
| Charles Rhyee | TD Cowen | Raises | Hold | $15.00 | $7.00 |
| Jailendra Singh | Truist Securities | Raises | Buy | $22.00 | $12.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | Outperform | $25.00 | $14.00 |
| Ann Hynes | Mizuho | Raises | Neutral | $13.00 | $11.00 |
| Luke Sergott | Barclays | Raises | Equal-Weight | $15.00 | $10.00 |
| Patrick Donnelly | Citigroup | Raises | Buy | $21.00 | $12.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fortrea Holdings. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fortrea Holdings compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Fortrea Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Fortrea Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Fortrea Holdings analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Fortrea Holdings
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Unraveling the Financial Story of Fortrea Holdings
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Fortrea Holdings's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 3.91%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Fortrea Holdings's net margin is impressive, surpassing industry averages. With a net margin of -2.27%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Fortrea Holdings's ROE excels beyond industry benchmarks, reaching -2.72%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Fortrea Holdings's ROA excels beyond industry benchmarks, reaching -0.57%. This signifies efficient management of assets and strong financial health.
Debt Management: Fortrea Holdings's debt-to-equity ratio surpasses industry norms, standing at 2.04. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.